Drug Device Combination Products Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Drug Device 
Combination Products 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  t o  the  la tes t  r epor t  by  IM ARC Group,  t i t l ed  "Drug  Devi ce  Combinat ion  
Products  M arket :  G loba l  I ndust ry  T rends,  Share ,  S ize ,  Growth ,  Oppor tun i ty  
and  Forecast  2024-2032, "  t he  g loba l  d rug  dev ice  combina t ion  p roduc t s  marke t  
s i ze  reached US$ 155 .3  B i l l i on  in  2023 .3
Report Factors Af fect ing  the  Growth  of  the  Drug Device  Combinat ion  Products  
Industry:
Growing Aging Populat ion:
Highlight and The  ag ing  g loba l  popu la t i on  i s  a  s i gn i f i can t  f ac to r  p rope l l i ng  t he  g rowth  o f  t he  
marke t .  W i t h  a  r i s i ng  number  o f  e l de r l y  i nd iv idua ls  wor l dw ide ,  t he  p reva lence o f  
Description ch ron ic  cond i t i ons ,  such  as  d iabet es ,  ca rd iovascu la r  d iseases ,  and  resp i ra t o r y  
d iso rders ,  i s  i nc reas ing .  Drug  dev ice  comb ina t ion  p roduc t s  p lay  a  v i t a l  par t  i n  
manag ing  these  a i lm en ts .  
As  peop le  age ,  t he i r  hea l thcare  needs  become more  comp lex ,  and  these  produc ts  
p rov ide  e f f i c ien t  and  conven ien t  so lu t ions .  Moreover ,  gove rn ing  agenc ies  a re  
under tak ing  i n i t i a t i ves  to  improve  hea l thca re  se rv ices ,  wh ich  i s  d r i v ing  the  
demand  f o r  d rug  dev ice  combina t i on  p roduc ts .
Regulatory Support:
Regulatory  suppor t  is  p lay ing a p ivota l  ro le  in  shaping the drug device 
combinat ion products market .  Regulatory bod ies are act ive ly  work ing to  
s t reaml ine approval  processes for  these products .  Th is  proact ive 
Report approach is  c reat ing a favorab le  env i ronment  for  manufacturers,  encouraging them to  invest  in  research and development  (R&D).  
Highlight and The shor ter  approval  t imel ines are expedi t ing the marke t  ent ry  o f  new and innovat ive drug device combinat ion products .  Manufacturers  can now 
nav igate regula tory  pathways more ef f ic ient ly ,  ensur ing that  safe  and 
Description usefu l  products  reach the market  sooner .
Technological  Advancements:
Ongoing technolog ica l  advancements  are revo lu t ion iz ing the drug device 
combinat ion products  market .  Innovat ive developments  are lead ing to  the 
creat ion of  more sophis t icated and user- f r iend ly  devices.  These products  
now of fer  enhanced drug de l ivery  mechanisms,  improved pat ient  
compl iance,  and increased safety .
Moreover ,  smar t  inha le rs  fo r  resp i ra to ry  cond i t ions  and  insu l in  pumps fo r  
d iabe tes  management  a re  p r ime examp les  o f  techno log ica l  b reak th roughs  in  
th is  f i e ld .  As  these  p roduc ts  become  more  advanced ,  hea l thca re  p rov ide rs  and  
pa t ien ts  inc reas ing ly  favor  them.  Techno log ica l  i nnova t ion  rema ins  a  key  
ca ta lys t  f o r  t he  con t inued  expans ion  o f  t he  d rug  dev ice  comb ina t ion  p roduc ts  
Report marke t .
Highlight and Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/drug-dev ice -comb ina t ion -p roduc ts -marke t / reques t
Description sample
Report Description
Global  Drug Device Combinat ion Products Market  Trends:
Hea l thcare  is  inc reas ing ly  sh i f t i ng  towards  a  pa t ien t -cen t r ic  mode l .  Drug  dev ice  comb ina t ion  p roduc ts  a l ign  
per fec t l y  w i th  th is  t rend ,  o f fe r ing  pa t ien ts  g rea te r  con t ro l  and  invo lvemen t  in  the i r  t rea tment .  These  p roduc ts  
empower  ind iv idua ls  to  manage  the i r  hea l th  cond i t ions  more  e f fec t i ve ly ,  lead ing  to  improved  ou tcomes  and  
qua l i t y  o f  l i fe .  
The  emphas is  on  pa t ien t -cen t r i c  ca re  by  hea l thcare  p rov ide rs  and  po l icymakers  i s  d r iv ing  the  adop t ion  o f  these  
p roduc ts ,  mak ing  them a  v i t a l  componen t  o f  modern  hea l thca re  de l i ve ry .  Drug  dev ice  comb ina t ion  p roduc ts  o f ten  
o f fe r  cos t -e f fec t ive  so lu t ions  fo r  bo th  pa t ien ts  and  hea l thcare  sys tems.  They  can  reduce  the  need  fo r  mu l t ip le  
med ica t ions ,  f requen t  hosp i ta l  v i s i t s ,  and  comp lex  t rea tment  reg imens .  Th is  no t  on ly  eases  the  f i nanc ia l  bu rden  
on  pa t ien ts  bu t  a l so  enhances  hea l thcare  sys tem e f f i c iency  by  lower ing  hosp i ta l i za t ion  ra tes  and  hea l thcare  
expend i tu res .
View Report  TOC,  F igures  and Tab les :  
https : / /www. imarcgroup.com/drug-dev ice -combinat ion-products -market
Breakup by Product:
• Drug Elut ing Stents
• Transdermal Patches
• Infus ion Pumps
• Drug Elut ing Bal loon
• Inhalers
Report • Others
Segmentation
Breakup by Application:
• Cardiovascular
• Diabetes
• Cancer Treatment
• Respiratory Diseases
• Others
Breakup by End User:
• Hospitals
• Ambulatory Surgical  Centers
• Others
Report Breakup by Region:
• North America
Segmentation • Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Abbott Laboratories
• Baxter International Inc.
• Bayer AG
• Becton Dickinson and Company
Competitive • Boston Scientifi c Corporation
Landscape • GlaxoSmithKline plc
•
with Key Johnson & Johnson
• Medtronic plc
Players • Novartis AG
• Smith & Nephew plc
• Stryker Corporation
• Terumo Corporation.
How has the global drug device combination 
products market performed so far, and how will it 
perform in the coming years?
What are the drivers, restraints, and opportunities 
in the global drug device combination products 
market?
Key What is the impact of each driver, restraint, and opportunity on the global drug device combination 
products market?
Questions 
Answered in What are the key regional markets?
the Report Which countries represent the most attractive drug 
device combination products market?
What is the breakup of the market based on the 
product?
Which is the most attractive product in the drug 
device combination products market?
What is the breakup of the market based on the 
application?
Which is the most attractive application in the drug 
device combination products market?
Key What is the breakup of the market based on the 
end user?
Questions 
Answered in Which is the most attractive end user in the drug device combination products market?
the Report
What is the competitive structure of the market?
Who are the key players/companies in the global 
drug device combination products market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  D r u g  D e v i c e  C o m b i n a t i o n  P r o d u c t s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  P r o d u c t
    6 . 1     D r u g  E l u t i n g  S t e n t s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     T r a n s d e r m a l  P a t c h e s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     I n f u s i o n  P u m p s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     D r u g  E l u t i n g  B a l l o o n
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     I n h a l e r s
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
    6 . 6     O t h e r s
        6 . 6 . 1  M a r k e t  T r e n d s
        6 . 6 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  A p p l i c a t i o n
    7 . 1     C a r d i o v a s c u l a r
Table of         7 . 1 . 1  M a r k e t  T r e n d s        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     D i a b e t e s
        7 . 2 . 1  M a r k e t  T r e n d s
Contents         7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     C a n c e r  T r e a t m e n t
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     R e s p i r a t o r y  D i s e a s e s
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     O t h e r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     H o s p i t a l s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /d ru g -dev i c e - c o m b i na t i o n -p ro duc
t s -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: